05:13 PM EDT, 03/21/2024 (MT Newswires) -- Lenz Therapeutics (LENZ) and Graphite Bio (GRPH) said late Thursday they have completed their business merger, with the combined companies operating as Lenz Therapeutics and trading under the LENZ ticker symbol beginning with Friday's regular session.

The company has been developing an aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, which presents as a difficulty to focus on nearby objects and text and is seen most often in older adults. It expects to report topline results from phase 3 testing of the eyedrops next month and file a new drug application for the prospective treatment by mid-year, the company said on Thursday.

Also on Thursday, Lenz said it has named Dan Chevallard to be its new chief financial officer, effective immediately. Chevallard most recently was CFO at Viracta Therapeutics (VIRX), the company said.